Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 10:56 PM
Ignite Modification Date: 2025-12-24 @ 10:56 PM
NCT ID: NCT03926169
Eligibility Criteria: Inclusion Criteria: * Participant with moderate to severe HS for at least 1 year prior to baseline visit. * HS lesions present in at least two distinct anatomical areas. * Draining fistula count of ≤ 20 at Baseline visit. * Total abscess and inflammatory nodule (AN) count of ≥ 5 at Baseline visit. * Participants are required to use a daily antiseptic wash on their HS lesions. * Participant must have a history of inadequate response or intolerance to an adequate trial of oral antibiotics for treatment of HS. Exclusion Criteria: * Participant has a history of active skin disease other than HS that could interfere with the assessment of HS. * Participant has active tuberculosis (TB) or concurrent treatment for latent TB or evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection. * Participant has prior exposure to anti-interleukin-1 (anti-IL-1) treatment within 3 months or 5 half-lives, whichever is longer, prior to baseline. * Participant has received prescription topical therapies (including topical antibiotics) within 14 days prior to the Baseline visit. * Participant has received systemic non-biologic therapies that can also be used to treat HS within 4 weeks prior to the Baseline visit. * Participant has received any systemic (including oral) antibiotic treatment within 4 weeks prior to the Baseline visit.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Study: NCT03926169
Study Brief:
Protocol Section: NCT03926169